Emapalumab for pediatric pHLH: pivotal study results

(11:43)

GAMIFANT® (emapalumab-lzsg) Mechanism of Disease \u0026 Mechanism of Action for Primary HLH

(8:24)

Real HLH Interview on Emapalumab Therapy

(26:17)

Emapalumab therapy interview with Dr. Bethany Verkamp

(6:40)

Dr.Gobind Rai Garg discusses the topic - Emapalumab

(1:25)

NextGen 2024: Real World Use of Emapalumab in MAS

(12:2)

FDA Approval of Gamifant® (emapalumab-Iszg) for Primary HLH Treatment

(10:)

Emapalumab mode of action

(1:23)

Michael Jordan, MD, Differentiates HLH Treatment in Pediatric Patients Versus Adults with Emapalumab

(2:31)

Is Emapalumab relevant for SJIA-LD patients - Fabrizio DeBenedetti

(14:34)

Primary HLH: Diagnosis and Treatment

(17:22)

Gamifant: Initiating Treatment

(11:17)

New Treatment Option for Primary Hemophagocytic Lymphohistiocytosis

(4:1econd)

Primary Haemophagocytic Lymphohistiocytosis: Overview and New Treatment Option

(5:13)

Gamifant: Starting Your Treatment

(5:49)

Emapalumab Treatment in Macrophage Activation Syndrome: Dr. Fabrizio De Benedetti

(1:13)

SOBI Overview at ASH: Data from Phase 2/3 Clinical Study of Emapalumab-lzsg in Primary HLH

(2:31)

Guiding Emapalumab Dosing in Primary Haemophagocytic Lymphohistiocytosis

(2:59)

Emapalumab

(2:47)